Evommune Inc. Common Stock (EVMN)

About EVMN

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The compan…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

48

Website

www.evommune.com/

Fundamentals

1-day range

$6.75$7.28

Market cap

$481.93M

P/E (trailing)

—

P/E (forward)

-1.95

EPS (trailing)

$-3.83

Dividend yield

—

Beta

0.62

Avg. volume

691.3K

Forecasts

8 analyst ratings

Evommune Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• EVMN

  Evommune Inc. Common Stock

  $5.17

  ▼ 12.82%
  Market cap $481.93MP/E —
  $6.52$33.2
• QTTB

  Q32 Bio Inc. Common Stock

  $7.52

  ▼ 3.22%
  Market cap $482.18MP/E 7.95
  $1.91$23.57
• EOLS

  Evolus Inc. Common Stock

  $7.1

  ▼ 6.21%
  Market cap $487.98MP/E —
  $3.86$9.31
• AQST

  Aquestive Therapeutics Inc. Common Stock

  $3.78

  ▼ 6.90%
  Market cap $491.83MP/E —
  $2.93$7.55
• OVID

  Ovid Therapeutics Inc. Common Stock

  $2.15

  ▼ 4.87%
  Market cap $494.60MP/E —
  $1.18$3.11
• TENX

  Tenax Therapeutics Inc. Common Stock

  $1.36

  ▼ 9.93%
  Market cap $498.11MP/E —
  $1.31$19.4
• BIOA

  BioAge Labs Inc. Common Stock

  $4.84

  ▼ 9.53%
  Market cap $500.98MP/E —
  $5.04$25.96

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
  Yahoo · 10/1/2026
• Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027
  Benzinga · 10/1/2026
• Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
  Yahoo · 9/23/2026
• Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
  Benzinga · 9/23/2026
• Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301
  SeekingAlpha · 9/22/2026
• Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
  Yahoo · 9/16/2026
• Evommune Consensus Price Target Decreased by 13.25% to $24.48
  Fintel · 9/15/2026
• Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
  Yahoo · 9/11/2026

• Carver Kyle · July 8, 2026 · Buy

  1.0K @ $13.26
• Arthur S. Kirsch · July 7, 2026 · Buy

  10.0K @ $13.3
• Patel Jeegar Pravinkumar · June 22, 2026 · Option Exercise

  1.5K @ $3.84
• Patel Jeegar Pravinkumar · June 22, 2026 · Sale

  1.5K @ $22.5
• Drew Janice Suzann · June 22, 2026 · Option Exercise

  16.2K @ $2.99
• Drew Janice Suzann · June 22, 2026 · Option Exercise

  3.8K @ $3.84
• Drew Janice Suzann · June 22, 2026 · Sale

  20.0K @ $22.63
• Pena Luis C. · June 22, 2026 · Sale

  7.4K @ $22.71
• Cohen David E · June 2, 2026 · Grant

  15.7K
• Cohen David E · June 2, 2026 · Sale

  600 @ $21.38
• Cohen David E · June 2, 2026 · Sale

  5.5K @ $20.21
• Arthur S. Kirsch · June 2, 2026 · Grant

  15.7K
• MCGRAW BENJAMIN F III · June 2, 2026 · Grant

  15.7K
• Patel Jeegar Pravinkumar · June 1, 2026 · Option Exercise

  13.5K @ $3.84
• Patel Jeegar Pravinkumar · June 1, 2026 · Sale

  16.7K @ $22.74

Institutional Ownership

March 31, 2026

Total shares held

32.89M

Total value held

$730.28M

Institutional holders

79